reslizumab
Respiratory system (R03)US regulatory status: approved. Molecular target: Interleukin-5.
- Target
- Interleukin-5
- Mechanism
- Interleukin-5 inhibitor
pharma · Multiple Myeloma · Neoplasms
Teva/Actavis Generics
Teva Generics B.V
Teva/Actavis Generics drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Salt Lake City, USA HQ
1992 Founded
100 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Salt Lake City, USA
- Founded
- 1992
- Employees
- 100
- Programs
- 4
- Drugs
- 1
- Patents
- 0
Teva/Actavis Generics pipeline
Portfolio lens on 1 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Teva/Actavis Generics drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.